Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study by T. De La Motte Rouge, J.-S. Frenel, C. Cropet, E. Borcoman, A. Hervieu, G. Emile, P. Augereau, E. Charafe, F. Legrand, E. Dassé, A. Gonçalves

Get full text

The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification by K. Rahmani Narj Abadi, C. Dupain, I. Guillou, R. Sanchez, K. Nedara, G. Marret, S. Hescot, M-P. Sablin, Z. Castel-Ajgal, C. Neuzillet, E. Borcoman, D. Bello Roufai, M. Rodrigues, A. Asnacios Lecerf, C. Callens, O. Trabelsi-Grati, S. Melaabi, K. Driouch, S. Antonio, E. Lemaitre, M. Nijnikoff, A. Vincent Salomon, Y. Allory, J. Cyrta, H. Ghazelian, E. Girard, N. Servant, D. Stoppa-Lyonnet, J. Wong, A. Hamza, J. Masliah-Planchon, M. Kamal, I. Bièche, C. Le Tourneau

Get full text